This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ESLOY or LZAGY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ESLOY vs. LZAGY: Which Stock Is the Better Value Option?
Lonza Group Ag (LZAGY) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Lonza Group Ag (LZAGY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The Zacks Analyst Blog Highlights: Moderna, Lonza Group, BMW, NXP Semiconductors and IDEXX Laboratories
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Lonza Group, BMW, NXP Semiconductors and IDEXX Laboratories
Vaccine Data Propels Stocks: Global Week Ahead
by John Blank
Moderna said in a Phase 3 trial, which enrolled 30K patients, its vaccine demonstrated 94.5% efficacy. The trial included "many high-risk or elderly" people. Furthermore, their vaccine can be stored a temperatures a commercial freezer can likely supply, easing distribution concerns.
Lonza Group Ag (LZAGY) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Lonza Group Ag (LZAGY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NUVA vs. LZAGY: Which Stock Is the Better Value Option?
by Zacks Equity Research
NUVA vs. LZAGY: Which Stock Is the Better Value Option?
LZAGY vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
LZAGY vs. BSX: Which Stock Is the Better Value Option?
3 Undervalued MedTech Stocks to Stay Safe From Trade War
by Sreyoshi Mukherjee
Amid U.S. market turmoil, a few stocks from the MedTech industry can prove profitable over the long haul.
LZAGY vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
LZAGY vs. BSX: Which Stock Is the Better Value Option?
5 Top-Ranked MedTech Growth Stocks for Solid Returns
by Zacks Equity Research
Despite the ongoing turmoil in the MedTech industry, these stocks with high growth potential can be great bets for investors.
Cardiovascular Systems (CSII) Catches Eye: Stock Jumps 6.9%
by Zacks Equity Research
Cardiovascular Systems (CSII) saw a big move last session, as its shares jumped nearly 7% on the day amid huge volumes.